In conclusion these data show that ibrutinib is an effective first-line treatment for patients with CLL carrying TP53 aberrations thanks to a nationwide real-world analysis of 747 patients treated at both large academic centers and community practice hospitals. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.